# Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases

> **NCT07246096** · EARLY_PHASE1 · RECRUITING · sponsor: **Changhai Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Autoimmune Diseases
- Systemic Lupus Erythematosus
- Systemic Sclerosis
- Primary Sjögren Syndrome
- Rheumatoid Arthritis
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

## Interventions

- **BIOLOGICAL:** anti-CD19/BCMA U CAR T cells

## Key facts

- **NCT ID:** NCT07246096
- **Lead sponsor:** Changhai Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-20
- **Primary completion:** 2027-07-20
- **Final completion:** 2028-07-20
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-02-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07246096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07246096, "Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07246096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*